ArticleMedComm2021
Clinical benefit of neoadjuvant anti-PD-1/PD-L1 utilization among different tumors.
Article in MedComm, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review.Frontiers in immunology · 2024Pooled it
- Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.The lancet. Gastroenterology & hepatology · 2022Trial
- Nanobodies and their derivatives: pioneering the future of cancer immunotherapy.Cell communication and signaling : CCS · 2025Review
- Co-Delivery of aPD-L1 and CD73 Inhibitor Using Calcium Phosphate Nanoparticles for Enhanced Melanoma Immunotherapy with Reduced Toxicity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Mechanism research of non-coding RNA in immune checkpoint inhibitors therapy.Cancer science · 2024Review
- Article
- Immunomodulatory Peptides as Vaccine Adjuvants and Antimicrobial Agents.Pharmaceuticals (Basel, Switzerland) · 2024Article
- The predictive value of a computed tomography-based radiomics model for the surgical separability of thymic epithelial tumors from the superior vena cava and the left innominate vein.Quantitative imaging in medicine and surgery · 2023Article
- Long noncoding RNA HITT coordinates with RGS2 to inhibit PD-L1 translation in T cell immunity.The Journal of clinical investigation · 2023Article
- Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.Cancer communications (London, England) · 2023Article
- ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.Journal for immunotherapy of cancer · 2023Article
- The Allelic Expression of RNA Editing GenePharmacogenomics and personalized medicine · 2023Article
- Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review).International journal of oncology · 2022Review
- PDL1Binder: Identifying programmed cell death ligand 1 binding peptides by incorporating next-generation phage display data and different peptide descriptors.Frontiers in microbiology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PD-1/PD-L1 (programmed cell death-1 and programmed death-ligand 1) inhibitors utilization in neoadjuvant therapy has been assessed in tumors. This study focused on the clinical benefits of neoadjuvant anti-PD-1/PD-L1 therapy. A comprehensive search was conducted in electronic databases to identify eligible studies. Major response rate (MRR) and complete response rate (CRR) were pooled in this analysis to assess the efficacy of neoadjuvant anti-PD-1/PD-L1 utilization, all grades and high-grade adverse events (AEs) were pooled to evaluate its safety. Twenty studies were included in this meta-analysis, with 828 patients suffering from different tumors. The pooled CRR of triple-negative breast cancer was 0.569 (95% CI 0.514, 0.624,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.